Skip to Content


Active Substance: elvitegravir
Common Name: elvitegravir
ATC Code: J05AX11
Marketing Authorisation Holder: Gilead Sciences International Ltd
Active Substance: elvitegravir
Status: Withdrawn
Authorisation Date: 2013-11-13
Therapeutic Area: HIV Infections
Pharmacotherapeutic Group: Antivirals for systemic use

Therapeutic Indication

Vitekta co-administered with a ritonavir-boosted protease inhibitor and with other antiretroviral agents, is indicated for the treatment of human-immunodeficiency-virus-1 (HIV-1) infection in adults who are infected with HIV-1 without known mutations associated with resistance to elvitegravir.

The marketing authorisation for Vitekta has been withdrawn at the request of the marketing-authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.